Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: Therapeutic prospects

Stefania Benini, Maria Cristina Manara, Vanessa Cerisano, Stefania Perdichizzi, Rosaria Strammiello, Massimo Serra, Piero Picci, Katia Scotlandi

Research output: Contribution to journalArticle

Abstract

Insulin-like growth factor receptor I (IGF-I)-mediated circuit is a major autocrine loop for Ewing's sarcoma (ES) cells and appears to be particularly important in the pathogenesis of this tumor. In this study, we analyzed the contribution of the 2 major pathways of the intracellular IGF-IR signaling cascade to the overall effects elicited by IGF-I in ES. Both the mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3-K) signaling pathways appeared to be constitutively activated in ES, likely due to the presence of the IGF-IR-mediated autocrine loop. We demonstrated that both MEK/MAPK (PD98059 or U0126) and PI3-K inhibitors (LY294002) profoundly impaired ES cell growth in monolayer and soft agar basal conditions. Both PD98059 and LY294002 inhibited ES cell cycle progression by inducing G I blockage, whereas only LY294002 significantly affected the survival of ES cells. Exogenous IGF-I completely reverted LY294002-induced growth inhibition by abrogating antiproliferative and proapoptotic effects of the PI3-K inhibitor. By contrast, IGF-I could not rescue cells from growth inhibition induced by PD98059. MEK/MAPK blockade also significantly reduced the migratory ability of ES cells, both in basal and IGF-I-induced conditions, and increased chemosensitivity to doxorubicin, a leader drug in the treatment of ES patients. Our findings therefore identify MAPK pathway as a promising target for pharmacologic intervention in ES.

Original languageEnglish
Pages (from-to)358-366
Number of pages9
JournalInternational Journal of Cancer
Volume108
Issue number3
DOIs
Publication statusPublished - Jan 20 2004

Fingerprint

Phosphatidylinositol 3-Kinase
Ewing's Sarcoma
Mitogen-Activated Protein Kinase Kinases
Mitogen-Activated Protein Kinases
IGF Type 1 Receptor
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
Therapeutics
Growth
Doxorubicin
Agar
Cell Cycle

Keywords

  • Ewing's sarcoma
  • Insulin-like growth factor I receptor
  • MAPK
  • PI3-K

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells : Therapeutic prospects. / Benini, Stefania; Manara, Maria Cristina; Cerisano, Vanessa; Perdichizzi, Stefania; Strammiello, Rosaria; Serra, Massimo; Picci, Piero; Scotlandi, Katia.

In: International Journal of Cancer, Vol. 108, No. 3, 20.01.2004, p. 358-366.

Research output: Contribution to journalArticle

@article{9c267aca464b442a9c8a6ca14b707fad,
title = "Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: Therapeutic prospects",
abstract = "Insulin-like growth factor receptor I (IGF-I)-mediated circuit is a major autocrine loop for Ewing's sarcoma (ES) cells and appears to be particularly important in the pathogenesis of this tumor. In this study, we analyzed the contribution of the 2 major pathways of the intracellular IGF-IR signaling cascade to the overall effects elicited by IGF-I in ES. Both the mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3-K) signaling pathways appeared to be constitutively activated in ES, likely due to the presence of the IGF-IR-mediated autocrine loop. We demonstrated that both MEK/MAPK (PD98059 or U0126) and PI3-K inhibitors (LY294002) profoundly impaired ES cell growth in monolayer and soft agar basal conditions. Both PD98059 and LY294002 inhibited ES cell cycle progression by inducing G I blockage, whereas only LY294002 significantly affected the survival of ES cells. Exogenous IGF-I completely reverted LY294002-induced growth inhibition by abrogating antiproliferative and proapoptotic effects of the PI3-K inhibitor. By contrast, IGF-I could not rescue cells from growth inhibition induced by PD98059. MEK/MAPK blockade also significantly reduced the migratory ability of ES cells, both in basal and IGF-I-induced conditions, and increased chemosensitivity to doxorubicin, a leader drug in the treatment of ES patients. Our findings therefore identify MAPK pathway as a promising target for pharmacologic intervention in ES.",
keywords = "Ewing's sarcoma, Insulin-like growth factor I receptor, MAPK, PI3-K",
author = "Stefania Benini and Manara, {Maria Cristina} and Vanessa Cerisano and Stefania Perdichizzi and Rosaria Strammiello and Massimo Serra and Piero Picci and Katia Scotlandi",
year = "2004",
month = "1",
day = "20",
doi = "10.1002/ijc.11576",
language = "English",
volume = "108",
pages = "358--366",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells

T2 - Therapeutic prospects

AU - Benini, Stefania

AU - Manara, Maria Cristina

AU - Cerisano, Vanessa

AU - Perdichizzi, Stefania

AU - Strammiello, Rosaria

AU - Serra, Massimo

AU - Picci, Piero

AU - Scotlandi, Katia

PY - 2004/1/20

Y1 - 2004/1/20

N2 - Insulin-like growth factor receptor I (IGF-I)-mediated circuit is a major autocrine loop for Ewing's sarcoma (ES) cells and appears to be particularly important in the pathogenesis of this tumor. In this study, we analyzed the contribution of the 2 major pathways of the intracellular IGF-IR signaling cascade to the overall effects elicited by IGF-I in ES. Both the mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3-K) signaling pathways appeared to be constitutively activated in ES, likely due to the presence of the IGF-IR-mediated autocrine loop. We demonstrated that both MEK/MAPK (PD98059 or U0126) and PI3-K inhibitors (LY294002) profoundly impaired ES cell growth in monolayer and soft agar basal conditions. Both PD98059 and LY294002 inhibited ES cell cycle progression by inducing G I blockage, whereas only LY294002 significantly affected the survival of ES cells. Exogenous IGF-I completely reverted LY294002-induced growth inhibition by abrogating antiproliferative and proapoptotic effects of the PI3-K inhibitor. By contrast, IGF-I could not rescue cells from growth inhibition induced by PD98059. MEK/MAPK blockade also significantly reduced the migratory ability of ES cells, both in basal and IGF-I-induced conditions, and increased chemosensitivity to doxorubicin, a leader drug in the treatment of ES patients. Our findings therefore identify MAPK pathway as a promising target for pharmacologic intervention in ES.

AB - Insulin-like growth factor receptor I (IGF-I)-mediated circuit is a major autocrine loop for Ewing's sarcoma (ES) cells and appears to be particularly important in the pathogenesis of this tumor. In this study, we analyzed the contribution of the 2 major pathways of the intracellular IGF-IR signaling cascade to the overall effects elicited by IGF-I in ES. Both the mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3-K) signaling pathways appeared to be constitutively activated in ES, likely due to the presence of the IGF-IR-mediated autocrine loop. We demonstrated that both MEK/MAPK (PD98059 or U0126) and PI3-K inhibitors (LY294002) profoundly impaired ES cell growth in monolayer and soft agar basal conditions. Both PD98059 and LY294002 inhibited ES cell cycle progression by inducing G I blockage, whereas only LY294002 significantly affected the survival of ES cells. Exogenous IGF-I completely reverted LY294002-induced growth inhibition by abrogating antiproliferative and proapoptotic effects of the PI3-K inhibitor. By contrast, IGF-I could not rescue cells from growth inhibition induced by PD98059. MEK/MAPK blockade also significantly reduced the migratory ability of ES cells, both in basal and IGF-I-induced conditions, and increased chemosensitivity to doxorubicin, a leader drug in the treatment of ES patients. Our findings therefore identify MAPK pathway as a promising target for pharmacologic intervention in ES.

KW - Ewing's sarcoma

KW - Insulin-like growth factor I receptor

KW - MAPK

KW - PI3-K

UR - http://www.scopus.com/inward/record.url?scp=0347626094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347626094&partnerID=8YFLogxK

U2 - 10.1002/ijc.11576

DO - 10.1002/ijc.11576

M3 - Article

C2 - 14648701

AN - SCOPUS:0347626094

VL - 108

SP - 358

EP - 366

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -